DÄ internationalArchive34-35/2007Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment

Review article

Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment

Dtsch Arztebl 2007; 104(34-35): A-2341

Griesshammer, M; Lengfelder, E; Döhner, K; Kvasnicka, H M; Thiele, J; Heimpel, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Griesshammer M, Gisslinger H, Heimpel H, Lengfelder E, Reiter A: Chronische myeloproliferative Erkrankungen. Leitlinien Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) 2006. www.dgho.de/cms/php?id=705
2. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–90. MEDLINE
3. Griesshammer M, Sauer T, Wenauer H, Bangerter M, Heimpel H: Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245: 295–300. MEDLINE
4. Thiele J, Kvasnicka HM: Chronische myeloproliferative Systemerkrankungen. Die neue WHO-Klassifikation. Pathologe 2001; 22: 429–43. MEDLINE
5. Lengfelder E, Hochhaus A, Kronawitter U et al.: Should a platelet limit of 600 3 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100: 15–23. MEDLINE
6. James C, Ugo V, Le Couedic JP et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–8. MEDLINE
7. Vannucchi AM, Antonioli E, Guglielmelli P et al.: Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 22: [Epub ahead of print]. MEDLINE
8. Wolanskyj AP, Schwager SM, McClure RF et al.: Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 8: 159–66. MEDLINE
9. Barbui T, Barosi G, Grossi A et al.: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–32. MEDLINE
10. Griesshammer M: Risk factors and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006; 32: 372–80. MEDLINE
11. Barosi G, Besses C, Birgegard G et al.: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2006; 21: 277–80. MEDLINE
12. Kiladjian JJ, Rain JD, Bernard JF et al.: Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32: 417–21. MEDLINE
13. Langer C, Lengfelder E, Thiele J et al.: Pegylated Interferon for the treatment of high-risk essential thrombocythemia – Results of a phase II Study. Haematologica 2005; 90: 1333–38. MEDLINE
14. Thiele J, Kvasnicka HM, Ollig S et al.: Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005; 20: 1071–6. MEDLINE
15. Fruchtman SM, Petitt RM, Gilbert HS et al.: Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005; 29: 481–91. MEDLINE
16. Cortelazzo S, Viero P, Bellavita P et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132–36. MEDLINE
17. Harrison CN, Campbell PJ, Buck G et al.: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45 MEDLINE
18. Griesshammer M, Struve S, Harrison C: Essential thrombocythemia/Polycythemia vera and pregnancy: the need for a observational study in Europe. Semin Thromb Hemost 2006; 32: 422–29. MEDLINE